Company intelligence / Profile preview

AnC Bio

Pyeongtaek, South Korea

Ownership: Private
Development stage: Other

Overview

AnC Bio promised transformative stem cell therapies and medical devices but failed to deliver. The artificial heart underwent Phase 1 testing with one patient death; stem cell therapies and artificial organ devices (kidney, liver) never advanced significantly through clinical development[4]

Therapeutic areas: CardiovascularNeurologyDermatology
Modalities: Stem cell therapy
Industry: Biotech

Partnerships

Stemedica International (joint venture for stem cell manufacturing)Japanese company (stem cell heart regeneration technology partnership mentioned but not named)

Beyond the preview

Go deeper on AnC Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnC Bio.

Explore the full profile